Activation of Peroxisome Proliferator-Activated Receptor δ Stimulates the Proliferation of Human Breast and Prostate Cancer Cell Lines

Cancer Research

Volumn 64, Issue 9, 2004, Pages 3162-3170

  Stephen, Ruth L ^a   Gustafsson, Mattias C U ^a   Jarvis, Morag ^a   Tatoud, Roger ^a   Marshall, Barry R ^a   Knight, Deborah ^a   Ehrenborg, Ewa ^b   Harris, Adrian L ^c   Wolf, C Roland ^a   Palmer, Colin N A ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

[2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; CELL NUCLEUS RECEPTOR; DOXYCYCLINE; HYDROCORTISONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; SEX HORMONE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ALPHA; VASCULOTROPIN RECEPTOR 1;

ANGIOGENESIS; ARTICLE; AUTOCRINE EFFECT; BINDING AFFINITY; BREAST CARCINOGENESIS; CANCER CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; CULTURE MEDIUM; DRUG RECEPTOR BINDING; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; REGULATORY MECHANISM; WESTERN BLOTTING;

BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; COLONIC NEOPLASMS; FEMALE; GENE EXPRESSION; GENES, CDC; GENES, REPORTER; HUMANS; LIGANDS; LUCIFERASES; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, ESTROGEN; RESPONSE ELEMENTS; RNA, MESSENGER; SIGNAL TRANSDUCTION; THIAZOLES; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS;

EID: 2342640982     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-2760     Document Type: Article

References (40)

1. Vosper H, Patel L, Graham TL, et al. The peroxisome proliferator-activated receptor δ promotes lipid accumulation in human macrophages. J Biol Chem 2001;276: 44258-65.
2. Barak Y, Liao D, He W, Ong ES, et al. Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci USA 2002;99:303-8.
3. Shi Y, Hon M, Evans RM. The peroxisome proliferator-activated receptor δ, an integrator of transcriptional repression and nuclear receptor signaling. Proc Natl Acad Sci USA 2002;99:2613-8.
4. Michalik L, Desvergne B, Tan NS, et al. Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)α and PPARδ mutant mice. J Cell Biol 2001; 154:799-814.
5. Peters JM, Lee SS, Li W, et al. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor β(δ). Mol Cell Biol 2000;20:5119-28.
6. Di-Poi N, Tan NS, Michalik L, Wahli W, Desvergne B. Antiapoptotic role of PPAR[β] in keratinocytes via transcriptional control of the Akt1 signaling pathway. Mol Cell 2002;10:721-33.
7. He TC, Chan TA, Vogelstein B, Kinzler KW. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999;99:335-45.
8. Gupta RA, Tan J, Krause WF, et al. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor δ in colorectal cancer. Proc Natl Acad Sci USA 2000;97:13275-80.
9. Shao J, Sheng H, DuBois RN. Peroxisome proliferator-activated receptors modulate K-Ras-mediated transformation of intestinal epithelial cells. Cancer Res 2002;62: 3282-8.
10. Park BH, Vogelstein B, Kinzler KW. Genetic disruption of PPAR[8] decreases the tumorigenicity of human colon cancer cells. Proc Natl Acad Sci USA 2001;98:2598-603.
11. Schirner M, Kraus C, Lichtner RB, Schneider MR, Hildebrand M. Tumor metastasis inhibition with the prostacyclin analogue cicaprost depends on discontinuous plasma peak levels. Prostaglandins Leukot Essent Fatty Acids 1998;58:311-7.
12. Glinghammar B, Skogsberg J, Hamsten A, Ehrenborg E. PPARδ activation induces COX-2 gene expression and cell proliferation in human hepatocellular carcinoma cells. Biochem Biophys Res Commun 2003;308:361-8.
13. Gupta RA, Wang D, Katkuri S, Wang H, Dey SK, DuBois RN. Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-8 accelerates intestinal adenoma growth. Nat Med 2004;10:245-7.
14. Maillard M, Cadot B, Ball RY, et al. Differential expression of the ccn3 (nov) proto-oncogene in human prostate cell lines and tissues. Mol Pathol 2001;54:275-80.
15. Oliver WR Jr, Shenk JL, Snaith MR, et al. A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 2001;98:5306-11.
16. Wei ZL, Kozikowski AP. A short and efficient synthesis of the pharmacological research tool GW501516 for the peroxisome proliferator-activated receptor δ. J Org Chem 2003;68:9116-8.
17. Landegren U. Measurement of cell numbers by means of the endogenous enzyme hexosaminidase. Applications to detection of lymphokines and cell surface antigens. J Immunol Methods 1984;67:379-88.
18. Harlow E, Lane D. Using antibodies: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1999.
19. Kumar V, Green S, Stack G, Berry M, Jin JR, Chambon P. Functional domains of the human estrogen receptor. Cell 1987;51:941-51.
20. Catherino WH, Jordan VC. The biological action of cDNAs from mutated estrogen receptors transfected into breast cancer cells. Cancer Lett 1995;90:35-42.
21. Tan NS, Michalik L, Noy N, et al. Critical roles of PPAR β/δ in keratinocyte response to inflammation. Genes Dev 2001;15:3263-77.
22. Foster JS, Henley DC, Ahamed S, Wimalasana J. Estrogens and cell-cycle regulation in breast cancer. Trends Endocrinol Metab 2001;12:320-7.
23. 1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J Biol Chem 1997;272:10882-94.
24. Dupont J, Karas M, LeRoith D. The potentiation of estrogen on insulin-like growth factor I action in MCF-7 human breast cancer cells includes cell cycle components. J Biol Chem 2000;275:35893-901.
25. Zhang J, Fu M, Zhu X, et al. Peroxisome proliferator-activated receptor δ is up-regulated during vascular lesion formation and promotes post-confluent cell proliferation in vascular smooth muscle cells. J Biol Chem 2002;277:11505-12.
26. Turner BC, Zhang J, Gumbs AA, et al. Expression of AP-2 transcription factors in human breast cancer correlates with the regulation of multiple growth factor signaling pathways. Cancer Res 1998;58:5466-72.
27. Werling U, Siehler S, Litfin M, Nau H, Gottlicher M. Induction of differentiation in F9 cells and activation of peroxisome proliferator-activated receptor δ by valproic acid and its teratogenic derivatives. Mol Pharmacol 2001;59:1269-76.
28. Price DJ, Miralem T, Jiang S, Steinberg R, Avraham H. Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ 2001;12:129-35.
29. Shureiqi I, Jiang W, Zuo X, et al. The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-δ to induce apoptosis in colorectal cancer cells. Proc Natl Acad Sci USA 2003;100:9968-73.
30. Chang WC, Nakao J, Orimo H, Murota S. Stimulation of prostacyclin biosynthetic activity by estradiol in rat aortic smooth muscle cells in culture. Biochim Biophys Acta 1980;619:107-18.
31. Sherman TS, Chambliss KL, Gibson LL, et al. Estrogen acutely activates prostacyclin synthesis in ovine fetal pulmonary artery endothelium. Am J Respir Cell Mol Biol 2002;26:610-6.
32. Seillan C, Ody C, Russo-Marie F, Duval D. Differential effects of sex steroids on prostaglandin secretion by male and female cultured piglet endothelial cells. Prostaglandins 1983;26:3-12.
33. Keller H, Givel F, Perroud M, Wahli W. Signaling cross-talk between peroxisome proliferator-activated receptor/retinoid X receptor and estrogen receptor through estrogen response elements. Mol Endocrinol 1995;9:794-804.
34. Newman SP, Bates NP, Vernimmen D, Parker MG, Hurst HC. Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer. Oncogene 2000;19: 490-7.
35. Perissi V, Menini N, Cottone E, et al. AP-2 transcription factors in the regulation of ERBB2 gene transcription by oestrogen. Oncogene 2000;19:280-8.
36. Dati C, Antoniotti S, Tavema D, Perroteau I, De Bortoli M. Inhibition of cerbB-2 oncogene expression by estrogens in human breast cancer cells. Oncogene 1990;5: 1001-6.
37. Fauconnet S, Lascombe I, Chabannes E, et al. Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells. J Biol Chem 2002;277:23534-43.
38. Bamba H, Ota S, Kato A, Kawamoto C, Fujiwara K. Prostaglandins up-regulate vascular endothelial growth factor production through distinct pathways in differentiated U937 cells. Biochem Biophys Res Commun 2000;273:485-91.
39. Yamakawa K, Hosoi M, Koyama H, et al. Peroxisome proliferator-activated receptor-γ agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells. Biochem Biophys Res Commun 2000;271:571-4.
40. Xin X, Yang S, Kowalski J, Gerritsen ME. Peroxisome proliferator-activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 1999;274:9116-21.